Monitoring AUPH open interest helps you see where real money is positioned on Aurinia Pharmaceuticals Inc's options and which strikes are attracting the most commitment from traders. Aurinia Pharmaceuticals Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor AUPH options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising AUPH options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Aurinia Pharmaceuticals Inc to settle.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where AUPH open interest is concentrated. Our scanner maps Aurinia Pharmaceuticals Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Aurinia Pharmaceuticals Inc's options open interest as the signal it is, not as an afterthought.
